Opiant Pharmaceuticals In... (OPNT)
NASDAQ: OPNT
· Real-Time Price · USD
20.65
0.00 (0.00%)
At close: Mar 01, 2023, 10:00 PM
Company Description
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose.
The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses.
Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016.
Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Opiant Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jun 4, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Roger Crystal |
Contact Details
Address: 233 Wilshirre Boulevard Santa Monica, California United States | |
| Website | https://www.opiant.com |
Stock Details
| Ticker Symbol | OPNT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001385508 |
| CUSIP Number | 683750103 |
| ISIN Number | US6837501039 |
| Employer ID | 46-4744124 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Roger Crystal M.D. | Pres, Chief Executive Officer & Director |
| David D. O'Toole | Chief Financial Officer |
| Ben Atkins | Vice President of Communications & Investor Relations |
| Brian Gorman | EVice President Corporation Devel. & Gen. Counsel |
| Dr. Mark Heath Ellison Ph.D. | Chief Devel. Officer |
| Dr. Phillip Skolnick D.Sc. (hon), Ph.D. | Chief Scientific Officer |
| Matthew R. Ruth | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 11, 2023 | CT ORDER | Filing |
| Mar 13, 2023 | 15-12G | Filing |
| Mar 06, 2023 | POS AM | Filing |
| Mar 06, 2023 | POS AM | Filing |
| Mar 06, 2023 | POS AM | Filing |
| Mar 06, 2023 | S-8 POS | Filing |
| Mar 06, 2023 | S-8 POS | Filing |
| Mar 06, 2023 | S-8 POS | Filing |
| Mar 06, 2023 | S-8 POS | Filing |
| Mar 06, 2023 | S-8 POS | Filing |